Provided by Tiger Trade Technology Pte. Ltd.

Akari Therapeutics PLC

10.56
+0.44004.35%
Volume:108.20K
Turnover:1.10M
Market Cap:20.56M
PE:-0.66
High:10.74
Open:10.26
Low:9.81
Close:10.12
52wk High:49.60
52wk Low:3.02
Shares:1.95M
Float Shares:694.50K
Volume Ratio:2.04
T/O Rate:15.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-15.9015
EPS(LYR):-20.5537
ROE:-140.09%
ROA:-19.10%
PB:1.11
PE(LYR):-0.51

Loading ...

European Equities Traded in the US as American Depositary Receipts Start Week Lower

MT Newswires Live
·
May 04

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week

MT Newswires Live
·
May 01

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading

MT Newswires Live
·
Apr 29

European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading

MT Newswires Live
·
Apr 27

BRIEF-Akari Therapeutics Secures Australian Patent Approval

Reuters
·
Apr 27

Akari Therapeutics wins Australian patent acceptance for Thailanstatin analog ADC payload

Reuters
·
Apr 27

Akari Therapeutics Plc - Aktx-101 in Ind-Enabling Studies With Phase 1 Trial Expected Late 2026/Early 2027

THOMSON REUTERS
·
Apr 27

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary Ph1 Rna Splicing Modulator ADC Payload

THOMSON REUTERS
·
Apr 27

European Equities Traded in US as ADRs Ease in Thursday Trading

MT Newswires Live
·
Apr 23

European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading

MT Newswires Live
·
Apr 21

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

GlobeNewswire
·
Apr 21

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires Live
·
Apr 20

Akari Therapeutics announces presentation of preclinical data for AKTX-101

TIPRANKS
·
Apr 20

Akari targets Q1 2027 start for Phase 1 trial of AKTX-101 ADC

Reuters
·
Apr 20

Akari Therapeutics Reports Positive Preclinical Data for Aktx-101 Demonstrating Differentiated Cytotoxicity for First-in-Class Trop2 ADC Payload Targeting Rna Splicing

THOMSON REUTERS
·
Apr 20

Akari CEO says WuXi XDC partnership accelerates AKTX-101 IND toward late 2026

Reuters
·
Apr 09

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership With WuXi XDC

THOMSON REUTERS
·
Apr 09

Akari Therapeutics Cut to Hold From Buy by Maxim Group

Dow Jones
·
Apr 08

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires Live
·
Apr 06

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:59 AM

Reuters
·
Apr 06